Answers are grounded in this paper and cite their sources.
We describe baseline characteristics from ENGAGE (NCT02477800) and EMERGE (NCT02484547), ongoing Phase 3 studies of similar designs evaluating aducanumab in patients with early AD (MCI due to AD or mild AD dementia).
No takes yet. Share an insight, caveat, or question.
Hehn et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: